An Open-label, Prospective Clinical Trial to Evaluate the Effectiveness and Safety of Sirolimus to Reduce Cyst Growth in ADPKD Patients With Massive Polycystic Liver

Next Previous
Trial Profile

An Open-label, Prospective Clinical Trial to Evaluate the Effectiveness and Safety of Sirolimus to Reduce Cyst Growth in ADPKD Patients With Massive Polycystic Liver

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Sirolimus (Primary)
  • Indications Autosomal dominant polycystic kidney disease
  • Focus Therapeutic Use
  • Acronyms SILVER

    • Most Recent Events

    • 24 Apr 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top